血清胆固醇水平与PTEN缺失前列腺癌转基因小鼠模型中的肿瘤生长
在PTEN缺失前列腺癌转基因小鼠模型中,使用依折麦布降低血清胆固醇并未显著影响腺癌发生率,但降低了前列腺内雄激素水平并减缓了肿瘤生长。血清胆固醇与前列腺重量、肿瘤上皮增殖正相关,与肿瘤上皮凋亡负相关。
要点
- 依折麦布降低血清胆固醇可降低前列腺内雄激素并减缓肿瘤生长。
- 血清胆固醇降低未显著影响该模型腺癌的发生率。
- 血清胆固醇与前列腺重量正相关,与肿瘤上皮凋亡负相关。
核心结论
- 降低血清胆固醇虽未显著影响PTEN缺失转基因小鼠前列腺癌模型中腺癌的发生率,但降低了前列腺内雄激素并减缓了肿瘤生长。
研究设计与样本
- PTENloxP/loxP-Cre+小鼠断奶后随机接受依折麦布30 mg/kg/天或无干预,于2、3、4月龄处死。
- 小鼠自由摄取高脂高胆固醇饮食(40%脂肪,1.25%胆固醇)。
主要发现
- 依折麦布组4月龄时血清胆固醇较低(p = 0.031)。
- 血清胆固醇与前列腺重量正相关(p = 0.033),与肿瘤上皮增殖正相关(p = 0.069),与肿瘤上皮凋亡负相关(p = 0.004)。
- 依折麦布组肿瘤基质细胞增殖减少(p = 0.010)。
- 4月龄时血清胆固醇升高与前列腺内DHEA、睾酮和雄烯二酮升高相关(p = 0.043、p = 0.074、p = 0.031)。
- 腺癌发生率在依折麦布组与非依折麦布组2、3、4月龄分别为0、78、100% vs 0、80、100%。
临床怎么用
- 降胆固醇干预可能通过降低前列腺内雄激素信号减缓前列腺癌生长,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Some, but not all, epidemiologic evidence supports a role for cholesterol, the precursor for steroid hormone synthesis, in prostate cancer. Using a PTEN-null transgenic mouse model of prostate cancer, we tested the effect of modifying serum cholesterol levels on prostate tumor development and growth. We hypothesized that serum cholesterol reduction would lower tumor androgens and slow prostate cancer growth. METHODS: PTENloxP/loxP-Cre+ mice consuming ad libitum high fat, high cholesterol diets (40% fat, 1.25% cholesterol) were randomized after weaning to receive the cholesterol uptake inhibitor, ezetimibe (30 mg/kg/day), or no intervention, and sacrificed at 2, 3, or 4 months of age. Serum cholesterol and testosterone were measured by ELISA and intraprostatic androgens by mass spectrometry. Prostate histology was graded, and proliferation and apoptosis in tumor epithelium and stroma was assessed by Ki67 and TUNEL, respectively. RESULTS: Ezetimibe-treated mice had lower serum cholesterol at 4 months (p = 0.031). Serum cholesterol was positively correlated with prostate weight (p = 0.033) and tumor epithelial proliferation (p = 0.069), and negatively correlated with tumor epithelial apoptosis (p = 0.004). Serum cholesterol was unrelated to body weight (p = 0.195). Tumor stromal cell proliferation was reduced in the ezetimibe group (p = 0.010). Increased serum cholesterol at 4 months was associated with elevated intraprostatic DHEA, testosterone, and androstenedione (p = 0.043, p = 0.074, p = 0.031, respectively). However, cholesterol reduction did not significantly affect adenocarcinoma development at 2, 3, or 4 months of age (0, 78, and 100% in ezetimibe-treated vs. 0, 80, and 100% in mice not receiving ezetimibe). CONCLUSIONS: Though serum cholesterol reduction did not significantly affect the rate of adenocarcinoma development in the PTEN-null transgenic mouse model of prostate cancer, it lowered intraprostatic androgens and slowed tumor growth. These findings support a role for serum cholesterol in promoting prostate cancer growth, potentially via enhanced tumor androgen signaling, and may provide new insight into cholesterol-lowering interventions for prostate cancer treatment.
引用
- Allott EH, Masko EM, Freedland AR, et al. Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer. Prostate Cancer Prostatic Dis. 2018. PMID: 29795142. doi:10.1038/s41391-018-0045-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。